Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation

Lin Wen Lee, Hui Chin Peng, Wun-Chang Ko, Wei Chun Hung, Ching Hua Su, Chien Huang Lin, Tur Fu Huang, Mao Hsiung Yen, Joen Rong Sheu

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

In this study, specific platelet activating factor (PAF) receptor antagonist ginkgolide B (BN52021) was tested for its antiplatelet activity in zymosan activated polymorphonuclear neutrophil-induced platelet aggregation. Triflavin was also tested for its antiplatelet activity compared with PAF receptor antagonist. Triflavin, an Arg-Gly-Asp-containing disintegrin purified from venom peptide inhibited platelet aggregation by interfering with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. Furthermore, we also report an efficient high resolution method for quantitative analysis of PAF using high-performance capillary electrophoresis (HPCE). The supernatant of polymorphonuclear neutrophils after their activation by opsonized zymosan induces the aggregation of washed rabbit platelets. In rabbit platelets, BN52021 (100-1000 μM) only partially inhibited activated polymorphonuclear neutrophil-induced platelet aggregation, and its maximal inhibition was estimated to be about 79%. Triflavin also partially inhibited platelet aggregation about 82% induced by activated polymorphonuclear neutrophils. Furthermore, after treatment with a combination of triflavin (0.26 μM) with various concentrations of BN52021 (4-1000 μM), the inhibitory effect of platelet aggregation was almost completely. This inhibition was greater than that produced by the individual drugs alone. These results indicate that a combination of glycoprotein IIb/IIIa complex and PAF receptor antagonist could completely inhibit activated polymorphonuclear neutrophil-induced platelet aggregation. In addition, the amount of PAF released from zymosan (6 mg/ml)-activated polymorphonuclear neutrophils was accurately calculated about 11.8±1.5 ng/106 cells, and did not further increase even at a high concentration of zymosan (10 mg/ml). These results suggest that PAF play a major role in the interaction between platelets and polymorphonuclear neutrophils. This interaction may be important in the pathogenesis of thrombosis and inflammatory diseases. Our present findings support the hypothesis that combination therapy with glycoprotein IIb/IIIa complex antagonists and PAF receptor antagonists may represent a new approach to the treatment of ischemic disorders. Copyright (C) 1999 Elsevier Science B.V.

Original languageEnglish
Pages (from-to)239-246
Number of pages8
JournalEuropean Journal of Pharmacology
Volume364
Issue number2-3
DOIs
Publication statusPublished - Jan 8 1999

Fingerprint

Platelet Aggregation
Neutrophils
Zymosan
Platelet Glycoprotein GPIIb-IIIa Complex
Platelet Activating Factor
ginkgolide B
Blood Platelets
Rabbits
Disintegrins
Venoms
Capillary Electrophoresis
platelet activating factor receptor
triflavin
Fibrinogen
Thrombosis
Peptides
Pharmaceutical Preparations

Keywords

  • BN52021
  • Disintegrin
  • PAF (platelet activating factor)
  • Platelet aggregation
  • Polymorphonuclear neutrophil
  • Triflavin

ASJC Scopus subject areas

  • Cellular and Molecular Neuroscience
  • Pharmacology

Cite this

Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation. / Lee, Lin Wen; Peng, Hui Chin; Ko, Wun-Chang; Hung, Wei Chun; Su, Ching Hua; Lin, Chien Huang; Huang, Tur Fu; Yen, Mao Hsiung; Sheu, Joen Rong.

In: European Journal of Pharmacology, Vol. 364, No. 2-3, 08.01.1999, p. 239-246.

Research output: Contribution to journalArticle

Lee, Lin Wen ; Peng, Hui Chin ; Ko, Wun-Chang ; Hung, Wei Chun ; Su, Ching Hua ; Lin, Chien Huang ; Huang, Tur Fu ; Yen, Mao Hsiung ; Sheu, Joen Rong. / Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation. In: European Journal of Pharmacology. 1999 ; Vol. 364, No. 2-3. pp. 239-246.
@article{28579e9e6fc6438197fae0ea99cdd53f,
title = "Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation",
abstract = "In this study, specific platelet activating factor (PAF) receptor antagonist ginkgolide B (BN52021) was tested for its antiplatelet activity in zymosan activated polymorphonuclear neutrophil-induced platelet aggregation. Triflavin was also tested for its antiplatelet activity compared with PAF receptor antagonist. Triflavin, an Arg-Gly-Asp-containing disintegrin purified from venom peptide inhibited platelet aggregation by interfering with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. Furthermore, we also report an efficient high resolution method for quantitative analysis of PAF using high-performance capillary electrophoresis (HPCE). The supernatant of polymorphonuclear neutrophils after their activation by opsonized zymosan induces the aggregation of washed rabbit platelets. In rabbit platelets, BN52021 (100-1000 μM) only partially inhibited activated polymorphonuclear neutrophil-induced platelet aggregation, and its maximal inhibition was estimated to be about 79{\%}. Triflavin also partially inhibited platelet aggregation about 82{\%} induced by activated polymorphonuclear neutrophils. Furthermore, after treatment with a combination of triflavin (0.26 μM) with various concentrations of BN52021 (4-1000 μM), the inhibitory effect of platelet aggregation was almost completely. This inhibition was greater than that produced by the individual drugs alone. These results indicate that a combination of glycoprotein IIb/IIIa complex and PAF receptor antagonist could completely inhibit activated polymorphonuclear neutrophil-induced platelet aggregation. In addition, the amount of PAF released from zymosan (6 mg/ml)-activated polymorphonuclear neutrophils was accurately calculated about 11.8±1.5 ng/106 cells, and did not further increase even at a high concentration of zymosan (10 mg/ml). These results suggest that PAF play a major role in the interaction between platelets and polymorphonuclear neutrophils. This interaction may be important in the pathogenesis of thrombosis and inflammatory diseases. Our present findings support the hypothesis that combination therapy with glycoprotein IIb/IIIa complex antagonists and PAF receptor antagonists may represent a new approach to the treatment of ischemic disorders. Copyright (C) 1999 Elsevier Science B.V.",
keywords = "BN52021, Disintegrin, PAF (platelet activating factor), Platelet aggregation, Polymorphonuclear neutrophil, Triflavin",
author = "Lee, {Lin Wen} and Peng, {Hui Chin} and Wun-Chang Ko and Hung, {Wei Chun} and Su, {Ching Hua} and Lin, {Chien Huang} and Huang, {Tur Fu} and Yen, {Mao Hsiung} and Sheu, {Joen Rong}",
year = "1999",
month = "1",
day = "8",
doi = "10.1016/S0014-2999(98)00815-2",
language = "English",
volume = "364",
pages = "239--246",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "2-3",

}

TY - JOUR

T1 - Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation

AU - Lee, Lin Wen

AU - Peng, Hui Chin

AU - Ko, Wun-Chang

AU - Hung, Wei Chun

AU - Su, Ching Hua

AU - Lin, Chien Huang

AU - Huang, Tur Fu

AU - Yen, Mao Hsiung

AU - Sheu, Joen Rong

PY - 1999/1/8

Y1 - 1999/1/8

N2 - In this study, specific platelet activating factor (PAF) receptor antagonist ginkgolide B (BN52021) was tested for its antiplatelet activity in zymosan activated polymorphonuclear neutrophil-induced platelet aggregation. Triflavin was also tested for its antiplatelet activity compared with PAF receptor antagonist. Triflavin, an Arg-Gly-Asp-containing disintegrin purified from venom peptide inhibited platelet aggregation by interfering with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. Furthermore, we also report an efficient high resolution method for quantitative analysis of PAF using high-performance capillary electrophoresis (HPCE). The supernatant of polymorphonuclear neutrophils after their activation by opsonized zymosan induces the aggregation of washed rabbit platelets. In rabbit platelets, BN52021 (100-1000 μM) only partially inhibited activated polymorphonuclear neutrophil-induced platelet aggregation, and its maximal inhibition was estimated to be about 79%. Triflavin also partially inhibited platelet aggregation about 82% induced by activated polymorphonuclear neutrophils. Furthermore, after treatment with a combination of triflavin (0.26 μM) with various concentrations of BN52021 (4-1000 μM), the inhibitory effect of platelet aggregation was almost completely. This inhibition was greater than that produced by the individual drugs alone. These results indicate that a combination of glycoprotein IIb/IIIa complex and PAF receptor antagonist could completely inhibit activated polymorphonuclear neutrophil-induced platelet aggregation. In addition, the amount of PAF released from zymosan (6 mg/ml)-activated polymorphonuclear neutrophils was accurately calculated about 11.8±1.5 ng/106 cells, and did not further increase even at a high concentration of zymosan (10 mg/ml). These results suggest that PAF play a major role in the interaction between platelets and polymorphonuclear neutrophils. This interaction may be important in the pathogenesis of thrombosis and inflammatory diseases. Our present findings support the hypothesis that combination therapy with glycoprotein IIb/IIIa complex antagonists and PAF receptor antagonists may represent a new approach to the treatment of ischemic disorders. Copyright (C) 1999 Elsevier Science B.V.

AB - In this study, specific platelet activating factor (PAF) receptor antagonist ginkgolide B (BN52021) was tested for its antiplatelet activity in zymosan activated polymorphonuclear neutrophil-induced platelet aggregation. Triflavin was also tested for its antiplatelet activity compared with PAF receptor antagonist. Triflavin, an Arg-Gly-Asp-containing disintegrin purified from venom peptide inhibited platelet aggregation by interfering with the interaction of fibrinogen with the glycoprotein IIb/IIIa complex. Furthermore, we also report an efficient high resolution method for quantitative analysis of PAF using high-performance capillary electrophoresis (HPCE). The supernatant of polymorphonuclear neutrophils after their activation by opsonized zymosan induces the aggregation of washed rabbit platelets. In rabbit platelets, BN52021 (100-1000 μM) only partially inhibited activated polymorphonuclear neutrophil-induced platelet aggregation, and its maximal inhibition was estimated to be about 79%. Triflavin also partially inhibited platelet aggregation about 82% induced by activated polymorphonuclear neutrophils. Furthermore, after treatment with a combination of triflavin (0.26 μM) with various concentrations of BN52021 (4-1000 μM), the inhibitory effect of platelet aggregation was almost completely. This inhibition was greater than that produced by the individual drugs alone. These results indicate that a combination of glycoprotein IIb/IIIa complex and PAF receptor antagonist could completely inhibit activated polymorphonuclear neutrophil-induced platelet aggregation. In addition, the amount of PAF released from zymosan (6 mg/ml)-activated polymorphonuclear neutrophils was accurately calculated about 11.8±1.5 ng/106 cells, and did not further increase even at a high concentration of zymosan (10 mg/ml). These results suggest that PAF play a major role in the interaction between platelets and polymorphonuclear neutrophils. This interaction may be important in the pathogenesis of thrombosis and inflammatory diseases. Our present findings support the hypothesis that combination therapy with glycoprotein IIb/IIIa complex antagonists and PAF receptor antagonists may represent a new approach to the treatment of ischemic disorders. Copyright (C) 1999 Elsevier Science B.V.

KW - BN52021

KW - Disintegrin

KW - PAF (platelet activating factor)

KW - Platelet aggregation

KW - Polymorphonuclear neutrophil

KW - Triflavin

UR - http://www.scopus.com/inward/record.url?scp=0032897866&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032897866&partnerID=8YFLogxK

U2 - 10.1016/S0014-2999(98)00815-2

DO - 10.1016/S0014-2999(98)00815-2

M3 - Article

C2 - 9932729

AN - SCOPUS:0032897866

VL - 364

SP - 239

EP - 246

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 2-3

ER -